| Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality (NCT03746054) | University Hospital, Angers | 2019-12-20 |
| The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans (NCT04126707) | Ascentage Pharma Group Inc. | 2019-11-19 |
| TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (NCT03849651) | St. Jude Children's Research Hospital | 2019-01-31 |
| Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors (NCT03615105) | Memorial Sloan Kettering Cancer Center | 2018-07-25 |
| EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors (NCT03481868) | University Hospital, Clermont-Ferrand | 2018-02-01 |
| Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation (NCT02790515) | St. Jude Children's Research Hospital | 2016-07-14 |
| Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib (NCT02733445) | Bristol-Myers Squibb | 2015-12-01 |
| Chronic Myeloid Leukemia (CML) Real-Life Database (NCT05963061) | University Hospital, Clermont-Ferrand | 2014-04-16 |
| Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase. (NCT01605981) | Novartis Pharmaceuticals | 2014-02-01 |
| Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population (NCT02363868) | Bristol-Myers Squibb | 2014-02-01 |
| Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders. (NCT01066468) | Novartis Pharmaceuticals | 2010-10-01 |
| Natural Killer Cells and Bortezomib to Treat Cancer (NCT00720785) | National Heart, Lung, and Blood Institute (NHLBI) | 2008-08-01 |
| Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers (NCT00488592) | National Heart, Lung, and Blood Institute (NHLBI) | 2007-06-01 |
| Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy (NCT00433745) | National Heart, Lung, and Blood Institute (NHLBI) | 2007-02-01 |
| Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (NCT00428909) | Novartis Pharmaceuticals | 2006-11-01 |
| Expanded Access Program of Ponatinib (NCT01592136) | Ariad Pharmaceuticals | |